Alkermes ' Sleeping Disorder Studies ' Data Look Excellent, Analyst Says

On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements…#alkermesplcalks #alks2680 #mwt #alks #placebo #ih #jefferies #alkermesalks2680
Source: Reuters: Health - Category: Consumer Health News Source Type: news